| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) (NCT05248659) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-04-05 |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) (NCT05248646) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-03-15 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) (NCT05162066) | BioCryst Pharmaceuticals | 2022-02-18 |
| Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) (NCT05200871) | Travere Therapeutics, Inc. | 2022-02-05 |
| Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (NCT05097989) | Alexion Pharmaceuticals, Inc. | 2022-01-14 |
| The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy. (NCT05132621) | Medical University of Warsaw | 2021-11-01 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (NCT05003986) | Travere Therapeutics, Inc. | 2021-08-12 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases (NCT04573920) | Novartis Pharmaceuticals | 2021-03-15 |
| Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (NCT04564339) | Alexion Pharmaceuticals, Inc. | 2021-01-19 |
| Atrasentan in Patients With IgA Nephropathy (NCT04573478) | Novartis Pharmaceuticals | 2020-12-11 |
| Safety and Efficacy Study of VIS649 for IgA Nephropathy (NCT04287985) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-07-20 |
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (NCT03762850) | Travere Therapeutics, Inc. | 2018-12-11 |
| First in Human Study to Assess Safety of VIS649 in Healthy Subjects (NCT03719443) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2018-10-09 |
| Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy (NCT02605525) | Baxalta now part of Shire | 2015-12-31 |
| Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (NCT02384317) | Amgen | 2015-03-27 |
| Development of a Metabolic Assessment Tool for Chronic Kidney Disease (NCT01838239) | University of California, Davis | 2008-06-01 |